Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer

Creative Commons License

Soydal Ç., Araz M., Ürün Y., Nak D., Özkan E., Küçük N. Ö.

QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, cilt.65, sa.3, ss.282-286, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 65 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.23736/s1824-4785.19.03165-0
  • Dergi Adı: QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.282-286
  • Anahtar Kelimeler: Prostatic neoplasms, Prostate-specific antigen, Survival, RADIOLIGAND THERAPY, RADIATION-DOSIMETRY, PSMA
  • Ankara Üniversitesi Adresli: Evet

Özet

BACKGROUND: This study aims to analyze the prognostic importance of serum prostate specific antigen (PSA) response in patients who received radioligand therapy (RLT) with Lu-177 Prostate-specific membrane antigen (PSMA) for their castration-resistant prostate cancer.